Societal cost-effectiveness analysis of the 21-gene assay in estrogen-receptor-positive, lymph-node-negative early-stage breast cancer in Japan.

BMC Health Serv Res 2014 Sep 5;14:372. Epub 2014 Sep 5.

Cedar Associates LLC, Menlo Park, CA, USA.

Background: Breast-cancer incidence and mortality have been increasing in Japan. Japanese-specific clinical validity and utility data for the 21-gene assay (Oncotype DX® Breast Cancer Assay; Genomic Health, Inc., Redwood City, USA) are now available. The objective of this study was to evaluate the cost-effectiveness of the 21-gene assay for the guidance of adjuvant chemotherapy decisions in estrogen-receptor-positive, lymph-node-negative, early-stage breast cancer patients, from the Japanese societal perspective.

Methods: The recurrence risk group distribution by the 21-gene assay result and the assay's influence on adjuvant chemotherapy recommendations were obtained from a study of 104 patients. A state-transition cohort (Markov) model tracked time from surgery until distant recurrence and from distant recurrence to death. Adjuvant chemotherapy benefit by 21-gene assay risk group was based on published clinical validation studies. Direct and indirect medical costs were obtained from the referral centers. Utilities associated with progression and chemotherapy-related adverse events were extracted from literature. Sensitivity analyses assessed the key drivers and robustness of the primary outcomes.

Results: The 21-gene assay identified 48% of patients as low-risk, 36% as intermediate-risk, and 16% as high-risk. Total acute chemotherapy-related costs decreased by ¥154,066 due to less adjuvant chemotherapy usage. In the high-risk group, adjuvant chemotherapy use increased 18%, leading to survival benefits. Chemotherapy use overall decreased by 19%. Monitoring costs increased by ¥3,744 but recurrence costs declined by ¥46,113 per patient. Use of the 21-gene assay increased quality-adjusted-life-years (QALYs) by 0.241 per patient on average; the net cost per QALY gained was ¥636,752 ($6,368).

Conclusions: The 21-gene assay for women with estrogen-receptor-positive, lymph-node-negative, early-stage breast cancer is projected to be cost-effective in Japan.

Download full-text PDF

Source
http://dx.doi.org/10.1186/1472-6963-14-372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165904PMC
September 2014
14 Reads

Publication Analysis

Top Keywords

21-gene assay
32
adjuvant chemotherapy
20
breast cancer
16
estrogen-receptor-positive lymph-node-negative
12
early-stage breast
12
lymph-node-negative early-stage
12
assay
9
risk group
8
21-gene
8
distant recurrence
8
chemotherapy
6
adjuvant
5
chemotherapy benefit
4
increased ¥3744
4
benefit 21-gene
4
based published
4
assay risk
4
group based
4
¥3744 recurrence
4
clinical validation
4

References

(Supplied by CrossRef)

K Kamo et al.
Jpn J Clin Oncol 2008

H Sonoo et al.
Breast Cancer 2005

K Yorozuya et al.
J Cancer Res Clin Oncol 2010

M Toi et al.
Jpn J Clin Oncol 2010

M Gnant et al.
Breast Care (Basel) 2011

MJ Hassett et al.
J Natl Cancer Inst 2006

KS Albain et al.
Lancet Oncol 2010

M Dowsett et al.
J Clin Oncol 2010

Similar Publications